2-[[4-(吡啶-2-基)哌嗪-1-基]甲基]-1H-苯并咪唑 | 70006-24-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 2-[[4-(吡啶-2-基)哌嗪-1-基]甲基]-1H-苯并咪唑
• 中文别名: 2-[(4-吡啶-2-基哌嗪-1-基)甲基]-1H-苯并咪唑
• 英文名称: ABT-724
• 英文别名: 2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]-1H-benzimidazole
• CAS: 70006-24-5
• 化学式: C₁₇H₁₉N₅
• 分子量: 293.371
• InChiKey: FRPJGTNLZNXQEX-UHFFFAOYSA-N

物化性质

• 溶解度：
  41.3 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  48
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P264,P280,P302+P352,P305+P351+P338,P332+P313,P337+P313,P362
• 危险性描述：
  H315,H319
• 储存条件：
  2-8°C，存储时建议使用惰性气体。

制备方法与用途

ABT-724 是一种有效且高度选择性的多巴胺D4受体激动剂，对人多巴胺D4受体的EC50值为12.4 nM。此外，它也是大鼠D4（EC50为14.3 nM）和雪貂D4受体（EC50为23.2 nM）的有效部分激动剂。ABT-724 对多巴胺D1、D2、D3或D5受体没有影响，且可用于治疗勃起功能障碍，并具有较少的副作用。

反应信息

• 作为反应物：
  描述：

  苄基碘 、 2-[[4-(吡啶-2-基)哌嗪-1-基]甲基]-1H-苯并咪唑 在 sodium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 反应 12.17h， 以68%的产率得到1-Benzyl-2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]benzimidazole
  参考文献：
  名称：

  Discovery of 2-(4-Pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a Dopaminergic Agent with a Novel Mode of Action for the Potential Treatment of Erectile Dysfunction

  摘要：

  A new class of agents with potential utility for the treatment of erectile dysfunction has been discovered, guided by the hypothesis that selective D-4 agonists are erectogenic but devoid of the side effects typically associated with dopaminergic agents. The lead agent 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (1, ABT-724) was discovered by optimization of a series of benzimidazole arylpiperazines. This highly selective D-4 agonist was found to be very potent and efficacious in vivo, eliciting penile erections in rats at a dose of 0.03 mumol/kg, with a positive response rate of 77% erectile incidence. Even at high doses, it was devoid of side effects in animal models of central nervous system behaviors, emesis, or nausea. The structure-activity relationship of the parent benzimidazole series leading to 1 is described, with the detailed in vitro and in vivo profiles described. Distinctive structural features were discovered that are associated with D-4 selective agonism in this series of analogues.

  DOI：

  10.1021/jm030505a
• 作为产物：
  描述：

  1-(2-吡啶基)哌嗪 在 三乙胺 作用下， 以 2-氯甲基苯并咪唑 、 水 、 N,N-二甲基甲酰胺 为溶剂， 以72%的产率得到2-[[4-(吡啶-2-基)哌嗪-1-基]甲基]-1H-苯并咪唑
  参考文献：
  名称：

  Benzimidazoles that are useful in treating sexual dysfunction

  摘要：

  本发明涉及使用式（I）的化合物治疗性功能障碍，以及含有式（I）的化合物用于治疗性功能障碍的组合物，其中 L为C 1-4 烷基； R A ，R B ，R C ，R D 和R E 如规范中所述； Z选自N、C和CH组成的群；以及 A为规范中描述的芳基和杂环芳基。

  公开号：

  US06960589B2

文献信息

• 1,2-Di(cyclic)substituted benzene compounds
  申请人：Kawahara Tetsuya

  公开号：US20050261291A1

  公开（公告）日：2005-11-24

  In one aspect, the present invention provides compounds having formula (1) or (100), a salt thereof or a hydrate of the foregoing, which compounds exhibit excellent cell adhesion inhibitory action or cell infiltration inhibitory action, and are useful as therapeutic or prophylactic agents for various inflammatory diseases and autoimmune diseases associated with adhesion and infiltration of leukocytes, such as inflammatory bowel disease (particularly ulcerative colitis or Crohn's disease), irritable bowel syndrome; rheumatoid arthritis, psoriasis, multiple sclerosis, asthma and atopic dermatitis. wherein R10 represents optionally substituted cycloalkyl, etc., R20-23 represent hydrogen, alkyl, alkoxy, etc., R30-32 represent hydrogen, alkyl, oxo, etc., and R40 represents optionally substituted alkyl, etc.

  在一个方面，本发明提供具有式（1）或（100）的化合物，其盐或前述的水合物，这些化合物表现出优异的细胞粘附抑制作用或细胞浸润抑制作用，并且可用作治疗或预防与白细胞粘附和浸润相关的各种炎症性疾病和自身免疫疾病的药物，例如炎症性肠病（尤其是溃疡性结肠炎或克罗恩病）、肠易激综合征；类风湿性关节炎、牛皮癣、多发性硬化、哮喘和特应性皮炎。 其中R10代表可选择地取代的环烷基等，R20-23代表氢、烷基、烷氧基等，R30-32代表氢、烷基、氧代基等，R40代表可选择地取代的烷基等。
• New indazole and indolone derivatives and their use pharmaceuticals
  申请人：Allerton Norfor Charlotte Moira

  公开号：US20050267096A1

  公开（公告）日：2005-12-01

  The present invention provides for compounds of formula (I), which are a class of dopamine agonists, more particularly a class of agonists that are selective for D3 over D2. These compounds are useful for the treatment and/or prevention of sexual dysfunction, for example female sexual dysfunction (FSD), in particular female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD; lack of interest in sex), female orgasmic disorder (FOD; inability to achieve orgasm); and male sexual dysfunction, in particular male erectile dysfunction (MED). Male sexual dysfunction as referred to herein is meant to include ejaculatory disorders such as premature ejaculation, anorgasmia (inability to achieve orgasm) or desire disorders such as hypoactive sexual desire disorder (HSDD; lack of interest in sex). These compounds are also useful in treating neuropsychiatric disorders and neurodegenerative disorders.

  本发明提供了一类多巴胺激动剂的化合物，具体来说是一类选择性作用于D3而非D2的激动剂。这些化合物可用于治疗和/或预防性功能障碍，例如女性性功能障碍（FSD），特别是女性性唤醒障碍（FSAD），性欲不振障碍（HSDD；对性欲缺乏兴趣），女性性高潮障碍（FOD；无法达到高潮）；以及男性性功能障碍，特别是男性勃起功能障碍（MED）。本文提到的男性性功能障碍包括射精障碍，如早泄，无法达到高潮的无性感（无法达到高潮）或性欲障碍，如性欲不振（HSDD；对性欲缺乏兴趣）。这些化合物还可用于治疗神经精神障碍和神经退行性疾病。
• [EN] SMALL MOLECULE INDUCERS OF GDNF AS POTENTIAL NEW THERAPEUTICS FOR NEUROPSYCHIATRIC DISORDERS<br/>[FR] PETITES MOLÉCULES INDUCTRICES DE GDNF COMME NOUVELLE THÉRAPEUTIQUE POSSIBLE DES TROUBLES NEUROPSYCHIATRIQUES
  申请人：UNIV COLUMBIA

  公开号：WO2013028999A1

  公开（公告）日：2013-02-28

  The invention provides a compound having the structure (I), wherein A is a substituted or unsubstituted ring; Z is present or absent and when present is (II), wherein n is 0, 1, 2, 3, or 4; Y is -(CR11R12)-, -NH(CR11R12)- or -O(CR11R12)- wherein R11 and R12 are each hydrogen or combine to form a carbonyl; and wherein R1 to R10 are herein as described.

  本发明提供了一种具有结构（I）的化合物，其中A是取代的或未取代的环；Z是否存在，如果存在则为（II），其中n为0，1，2，3或4；Y是-(CR11R12)-，-NH(CR11R12)-或-O(CR11R12)-，其中R11和R12分别是氢或结合形成一个羰基；以及其中R1至R10如本文所述。
• [EN] AMINOPYRIDINE DERIVATIVES AS SELECTIVE DOPAMINE D3 AGONISTS<br/>[FR] DERIVES D'AMINOPYRIDINE UTILISES COMME AGONISTES SELECTIFS DE LA DOPAMINE D3
  申请人：PFIZER LTD

  公开号：WO2005115985A1

  公开（公告）日：2005-12-08

  The present invention provides for compounds of formula (I) which are a class of dopamine agonists, more particularly a class of agonists that are selective for D3 over D2. These compounds are useful for the treatment and/or prevention of sexual dysfunction, for example female sexual dysfunction (FSD), in particular female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD; lack of interest in sex), female orgasmic disorder (FOD; inability to achieve orgasm); and male sexual dysfunction, in particular male erectile dysfunction (MED). Male sexual dysfunction as referred to herein is meant to include ejaculatory disorders such as premature ejaculation, anorgasmia (inability to achieve orgasm) or desire disorders such as hypoactive sexual desire disorder (HSDD; lack of interest in sex). These compounds are also useful in treating neuropsychiatric disorders and neurodegenerative disorders.

  本发明提供了一类化合物(I)，这些化合物是多巴胺激动剂的一类，更具体地说是一类选择性作用于D3而非D2的激动剂。这些化合物对于治疗和/或预防性功能障碍非常有用，例如女性性功能障碍（FSD），特别是女性性唤醒障碍（FSAD），性欲不振障碍（HSDD；对性欲缺乏兴趣），女性性高潮障碍（FOD；无法达到高潮）；以及男性性功能障碍，特别是男性勃起功能障碍（MED）。本文提到的男性性功能障碍包括射精障碍，如早泄，无法达到高潮（无法达到高潮）或性欲障碍，如性欲不振障碍（HSDD；对性欲缺乏兴趣）。这些化合物还可用于治疗神经精神障碍和神经退行性疾病。
• [EN] HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS UTILISATIONS DANS LE TRAITEMENT DE TROUBLES SEXUELS
  申请人：ATIR HOLDING S A

  公开号：WO2012140642A1

  公开（公告）日：2012-10-18

  Biologically active compounds, which are useful for treating a sexual disorder, are provided herein. Further provided are pharmaceutical compositions formulated for transdermal composition, which comprise a biologically active compound useful for treating a sexual disorder. The compounds and pharmaceutical compositions allow for a prolonged presence of a biologically active compound in plasma. Further provided herein are methods and uses of the compounds and pharmaceutical compositions described herein in the treatment of a sexual disorder, including female sexual disorders.

  本文提供了对治疗性功能障碍有用的生物活性化合物。此外，还提供了用于透皮给药的药物组合物，其中包含一种对治疗性功能障碍有用的生物活性化合物。这些化合物和药物组合物可以使生物活性化合物在血浆中持续存在。此外，本文还提供了上述化合物和药物组合物在治疗性功能障碍中的方法和用途，包括女性性功能障碍。